(Service Trade Fair 2020) Service Trade Fair Business Opportunity: Can the Chinese-made new crown vaccine be used globally?

　　China News Service, Beijing, September 7 (Wan Shuyan) The new crown pneumonia epidemic is still spreading in many countries, and vaccine developers around the world are racing against the virus.

During the 2020 China International Trade in Services Fair, three new inactivated vaccines independently developed by China made their public appearances for the first time, which seems to be one step closer to the market.

Can China's new crown vaccine be widely used in the global market in the future?

　　Today, China's new crown vaccine research and development is "speeding up."

The latest data from the World Health Organization show that more than 30 new crown vaccines worldwide have entered the clinical trial stage, of which 9 new crown vaccines are in the third phase of clinical trials.

Among these, four vaccines developed in China alone have been approved for overseas Phase III clinical trials.

　　In the public health and epidemic prevention zone of the Service and Trade Fair in 2020, two vaccines developed by Sinopharm Sinopharm and one vaccine developed by Kexing Holdings were shown to the public for the first time. They are all new crown inactivated vaccines.

The two connected booths were surrounded by water and many visitors sighed "China Speed" while taking photos.

In addition to vaccines, anti-epidemic products such as COVID-19 human immunoglobulin and nucleic acid detection kits were also exhibited.

　　Zhang Yuntao, vice president of Sinopharm Group China Biology, told a reporter from China News Agency that the two vaccines were developed by two biological product research institutes in Wuhan and Beijing under Sinobiology, and are currently being launched in the UAE, Bahrain, Peru, Morocco, Argentina and other countries and regions. In the third phase of the clinical trial, 50,000 people were vaccinated and samples covered 115 countries.

"If the overseas clinical trials progress smoothly, the vaccine is expected to be available by the end of this year."

　　The vaccine "Kierlaifu" developed by Kexing Holdings is currently undergoing Phase III clinical trials in Brazil, Indonesia, Turkey, Bangladesh and other countries.

Yin Weidong, chairman of Kexing Holding Biotechnology Co., Ltd., revealed that the speed of research in Brazil is progressing very fast and plans to enroll 9,000 people in the group.

After the vaccine is proven effective overseas, the next step can be launched, "We hope to get clinical results before the end of the year."

　　Is the vaccine effective against viruses around the world?

Yin Weidong said that Kexing obtained more than 20 strains of viruses with different sequences in the United States, Europe, the Middle East and other places. The vaccine immune serum can neutralize these viruses. It can be inferred that vaccines can protect the world.

"The inactivated new coronavirus vaccine can be stored at 37 degrees Celsius for one month, and the validity period is initially determined to be three years."

　　In addition to the time to market, the public is most concerned about whether the vaccine supply can keep up.

The reporter learned during the interview that the initial annual output of the two companies mentioned above can reach 600 million doses.

　　China Biological has established high-level biosafety production facilities in two biological product research institutes in Beijing and Wuhan. The combined annual production capacity of the two workshops in the first phase can reach 300 million doses.

After the second phase is completed, the annual output value will reach 1 billion doses.

Kexing Biological launched the new crown inactivated vaccine industrialization project at the end of March this year, and has completed the construction of the production workshop in the Daxing Biomedical Industry Base, which can produce 300 million doses per year.

　　In addition to these three vaccines, China has a variety of vaccines that are stepping up research and development.

It is foreseeable that if the progress goes well, vaccine production will continue to expand.

　　Since the outbreak of the epidemic, China has deployed a total of 12 R&D tasks in accordance with the five technical routes of inactivated vaccines, recombinant protein vaccines, adenovirus vector vaccines, attenuated influenza virus vector live vaccines, and nucleic acid vaccines.

Currently, 9 vaccines developed in China have entered clinical trials.

　　Although the time to market the vaccine has not yet been determined, many countries have already offered Chinese companies an "olive branch".

Zhang Yuntao revealed that China Biotech has received orders from dozens of countries with a total of 500 million doses.

　　"The future application of vaccines will give priority to three types of countries and regions, namely countries with severe epidemics, countries with large populations, and countries without medical research and development capabilities and supplies." Yin Weidong said that Kexing has also obtained intentional orders from many countries.

On August 20, Kexing Zhongwei and PT BioFarma, a state-owned pharmaceutical company in Indonesia, signed the "Preliminary Agreement on the Purchase and Supply of New Crown Vaccine Bulk Products" and a memorandum of understanding for follow-up cooperation, stipulating that Kexing Zhongwei will be in November 2020 to 2021. In March, 40 million doses of semi-finished products of the new crown vaccine were supplied, and the intention to supply semi-finished vaccines for the whole year of 2021 was reached. PT BioFarma will be responsible for completing the filling and packaging of vaccines in Indonesia and supplying vaccines to the Indonesian people.

　　Chinese officials promise that after the new crown vaccine is completed and put into use, it will serve as a global public product and make China's contribution to the realization of the vaccine's accessibility and affordability in developing countries.

　　The theme of this service trade fair is "Global Service, Mutual Benefit Sharing".

As Gauden Galea, the representative of the World Health Organization in China, said at the meeting, defeating the epidemic requires global cooperation and hopes that the world will work together to find the most effective way to deal with the new crown virus.

Vaccine research and development has made great progress, and China is leading in this regard.

WHO will continue to cooperate with China and all member states to formulate strategic plans to jointly fight the epidemic.

(Finish)